• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

What’s Trending in Monoclonal Antibodies (Market by Structure [Chimeric, Humanized], by Target [EGFR, TNF, HER2, CD20,PD-1, Other] and by Disease [Autoimmune, Oncology, Neurological, Other])

$4,500.00 – $9,000.00

Clear
SKU: KLI15596716 Category: Biotechnology Market Research Pages: 203
  • Description
  • Table of Contents
  • Latest reports

Description

What’s Trending in Monoclonal Antibodies (Markets by Structure, by Target, and by Indication)

There are several types of monoclonal antibodies (mAbs) – large protein molecules produced by white blood cells (WBCs) that seek out and destroy harmful foreign substances – on the market and in development. What’s Trending in Monoclonal Antibodies looks at the market for these, which are finding wide application in many areas of medicine and biologic science, by structure, by target, and by indication, including the following information: monoclonal antibody revenues by structure, 2017 and forecast 2022 (chimeric, humanized, human, Others); leading chimeric, humanized and human mAb products market, 2017-2022; monoclonal antibody revenues by target, 2017 and forecast 2022 (TNF, CD20, HER2, VEGF, EGFR, PD-1, PD-L1, TNFSF11, IL12/IL23, IL17, IL6, Others); and monoclonal antibody revenues by indication, 2017 and Forecast 2022 (Autoimmune, Oncology, Neurological, Respiratory, Cardio/Blood, Infection, Other).

The report also goes beyond broad indication category to provide detail on the rheumatoid arthritis, Crohn’s disease/ulcerative colitis, psoriasis, other autoimmune, cancer (breast cancer, colon cancer, lymphoma, leukemia, myeloma, melanoma), multiple sclerosis, asthma, and macular degeneration mAb market segments, 2017-2022.

What’s Trending in Monoclonal Antibodies also looks at the market in terms of regional markets (United States, Europe, rest of world, global market) and the competitive situation, including company profiles of market leaders such as AbbVie, Johnson & Johnson, and Roche.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARYOVERVIEW

Figure 1-1: Monoclonal Antibody Market Development, 1986-2022

SCOPE AND METHODOLOGYMARKET SUMMARY

Figure 1-2: Monoclonal Antibody Market, 2017-2022 ($ millions)

CHAPTER TWO: INTRODUCTIONTHE DEVELOPMENT OF MONOCLONAL ANTIBODIES

Figure 2-1: Monoclonal Antibody Approvals by Year, FDA and EMA, 1990 through December 2017

NAMING MONOCLONAL ANTIBODIES

Table 2-1: Monoclonal Antibody Source Identifiers
Table 2-2: Monoclonal Antibody Disease or Target Class Identifiers
Table 2-3: Examples of Monoclonal Antibodies by Name Origin

New Monoclonal Antibody Nomenclature Rules

Table 2-4: USAN Requirements for Monoclonal Antibodies

DEVELOPMENT OUTLOOK

Table 2-5: Monoclonal Antibody Development Pipeline by Therapeutic Class and Phase, 2017 (Oncology, Autoimmune, Respiratory Disorders, Neurological Disorders, Infectious Diseases, Cardiovascular Disease/Blood Disorders, Genetic Disorders, Others, Total)
Figure 2-2: Monoclonal Antibody Development Pipeline by Therapeutic Class and Phase, 2017 (Oncology, Autoimmune, Respiratory Disorders, Neurological Disorders, Infectious Diseases, Cardiovascular Disease/Blood Disorders, Genetic Disorders, Others)
Figure 2-3: Monoclonal Antibody Development Pipeline, Distribution of Projects by Therapeutic Class, 2017 (Oncology, Autoimmune, Respiratory Disorders, Neurological Disorders, Infectious Diseases, Cardiovascular Disease/Blood Disorders, Genetic Disorders, Others)
Figure 2-4: Monoclonal Antibody Development Pipeline, Distribution of Projects by Phase, 2017 (Registration, Phase I, Phase II, Phase III)

CHAPTER THREE: MONOCLONAL ANTIBODY MARKETS BY STRUCTURE

Figure 3-1: Monoclonal Antibodies by Structure – Mouse, Chimeric, Humanized, Human

MARKET OVERVIEW

Table 3-1: Monoclonal Antibody Market by Structure, 2017 and Forecast 2022 ($ millions) (Chimeric, Humanized, Human, Others, Total)
Figure 3-2: Monoclonal Antibody Market by Structure, 2017 and Forecast 2022 ($ millions) (Chimeric, Humanized, Human, Others)
Figure 3-3: Monoclonal Antibody Market Distribution by Structure, 2017 (%) (Chimeric, Humanized, Human, Others)
Figure 3-4: Monoclonal Antibody Market Distribution by Structure, 2022 (%) (Chimeric, Humanized, Human, Others)

Chimeric

Table 3- 2: Leading Products: Chimeric Structure mAb Market, 2017-2022 ($ millions)
Humanized
Table 3-3: Leading Products: Humanized Structure mAb Market, 2017-2022 ($ millions)

Human

Table 3-4: Leading Products: Human Structure mAb Market, 2017-2022 ($ millions)

CHAPTER FOUR: MONOCLONAL ANTIBODY MARKETS BY TARGETMARKET OVERVIEW

Figure 4-1: Monoclonal Antibodies by Target – TNF, CD20, HER2, VEGF, EGFR, PD-L1, PD-1, TNFSF11, IL12/IL23, IL17, IL6 Examples
Table 4-1: Monoclonal Antibody Market by Target, 2017 and Forecast 2022 ($ millions) (TNF, VEGF, HER2, PD-1, CD20, IL12/IL23, TNFSF11, IL17, EGFR, IL6, PD-L1, Others, Total)
Figure 4-2: Monoclonal Antibody Market by Target, 2017 and Forecast 2022 ($ millions) (TNF, CD20, HER2, VEGF, EGFR, PD-1, PD-L1, TNFSF11, IL12/IL23, IL17, IL6, Others)
Figure 4-3: Monoclonal Antibody Market Distribution by Target, 2017 (%) (TNF, CD20, HER2, VEGF, EGFR, PD-L1, PD-1, TNFSF11, IL12/IL23, IL17, IL6, Others)
Figure 4-4: Monoclonal Antibody Market Distribution by Target, 2022 (%) (TNF, CD20, HER2, VEGF, EGFR, PD-L1, PD-1, TNFSF11, IL12/IL23, IL17, IL6, Others)

CHAPTER FIVE: MONOCLONAL ANTIBODY MARKETS BY INDICATIONMARKET OVERVIEW

Table 5-1: Monoclonal Antibody Market by Indication, 2017 and Forecast 2022 ($ millions) (Autoimmune, Oncology, Neurological, Respiratory, Cardio/Blood, Infection, Other, Total)
Figure 5-1: Monoclonal Antibody Market by Indication, 2017 and Forecast 2022 ($ millions) (Autoimmune, Oncology, Neurological, Respiratory, Cardio/Blood, Infection, Other)
Figure 5-2: Monoclonal Antibody Market Distribution by Indication, 2017 (%) (Autoimmune, Oncology, Neurological, Respiratory, Cardio/Blood, Infection, Other)
Figure 5-3: Monoclonal Antibody Market Distribution by Indication, 2022 (%) (Autoimmune, Oncology, Neurological, Respiratory, Cardio/Blood, Infection, Other)

Autoimmune Diseases

Table 5-2: Rheumatoid Arthritis mAb Market, 2017-2022 ($ millions)
Table 5-3: Crohn’s Disease/Ulcerative Colitis mAb Market, 2017-2022 ($ millions)
Table 5-4: Psoriasis mAb Market, 2017-2022 ($ millions)
Table 5-5: Other Autoimmune Disease mAb Market, 2017-2022 ($ millions)

Oncology Indications

Table 5-6: Cancer Treatment mAb Market by Type, 2017-2022 ($ millions) (Breast Cancer, Colon Cancer, Lymphoma, Leukemia, Myeloma, Melanoma)
Table 5-7: Top 10 Cancer Indicated Monoclonal Antibodies, 2016 and 2017 Sales (millions $)
Figure 5-4: Top 10 Cancer Indicated Monoclonal Antibodies, 2016 and 2017 Sales (millions $)

Neurological Indications

Table 5-8: Multiple Sclerosis mAb Market, 2017-2022 ($ millions)

Respiratory Treatments

Table 5-9: Asthma mAb Market, 2017-2022 ($ millions)

OTHER AREAS OF TREATMENT

Table 5-10: Macular Degeneration mAb Market, 2017-2022 ($ millions)

CHAPTER SIX: MARKET SUMMARYMARKET INFLUENCESGlobal Demographics

Table 6-1: Global Population, through 2050 (population in millions)
Figure 6-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050

Chronic Diseases

Figure 6-2: Mortality: Chronic vs. Acute, 2015

Cost Containment

Table 6-2: The Cost of Monoclonal Antibodies (Soliris, Ilaris, Erbitux, Opdivo, Avastin, Yervoy, Stelara, Xolair, Perjeta, Tysabri, Cosentyx, Simponi, Vectibix, Herceptin, Humira, Entyvio, Rituxan, Synagis, Remicade)

REIMBURSEMENT LANDSCAPE: A DECIDING FACTOR FOR SUCCESSTHE BIOSIMILAR MOVEMENTREGIONAL MARKET OVERVIEW

Table 6-3: Monoclonal Antibody Market Summary by Geographical Region, 2017-2022 ($ millions) (United States, Europe, Rest of World, Global Market)
Figure: 6-3: Monoclonal Antibody Market Summary by Geographic Region, 2017 ($ millions) (United States, Europe, Rest of World)

LEADING PRODUCTS

Table 6-4: Leading Monoclonal Antibodies based on 2017 Sales ($ millions)

MARKET BREAKDOWN OF MONOCLONAL ANTIBODIES

Figure 6-4: Monoclonal Antibody Market by Structure, 2017 and 2022 ($ millions) (Chimeric, Humanized, Human, Others)
Figure 6-5: Monoclonal Antibody Market by Target, 2017 and 2022 ($ millions) (TNF, CD20, HER2, VEGF, EGFR, PD-L1, PD-1, TNFSF11, IL12/IL23, IL17, IL6, Others)
Figure 6-6: Monoclonal Antibody Market by Indication, 2017 and 2022 ($ millions) (Rheumatoid Arthritis, Breast Cancer, Melanoma, Crohn’s Disease/Ulcerative Colitis, Colon Cancer, Lymphoma, Psoriasis, Macular Degeneration, Asthma, Multiple Sclerosis, Osteoporosis, Myeloma, RSV, Leukemia, Other Indications)

COMPETITOR SUMMARY

Genentech/Roche
AbbVie
Janssen Biotech/J&J
Bristol-Myers Squibb
Merck & Co
Novartis
Amgen
Alexion
Biogen
Eli Lilly & Co.
Table 6-5: Monoclonal Antibody Competitor Market Share, 2017 ($ millions)

CHAPTER SEVEN: COMPANY PROFILESABBVIE

Table 7-1: AbbVie Corporate Summary

ABLYNX

Table 7-2: Ablynx Corporate Summary

AGENSYS

Table 7-3: Agensys (with Astellas) Corporate Summary

ALDER BIOPHARMACEUTICALS

Table 7-4: Alder Biopharmaceuticals Corporate Summary

ALEXION PHARMACEUTICALS

Table 7-5: Alexion Pharmaceuticals Corporate Summary

ALLERGAN

Table 7-6: Allergan Corporate Summary

AMGEN

Table 7-7: Amgen Corporate Summary

APTEVO THERAPEUTICS

Table 7-8: Aptevo Corporate Summary

ASTRAZENECA/MEDIMMUNE

Table 7-9: AstraZeneca/MedImmune Corporate Summary

BAYER

Table 7-10: Bayer Corporate Summary

BIOCON LTD

Table 7-11: Biocon Corporate Summary

BIOGEN INC.

Table 7-12: Biogen Corporate Summary

BIOINVENT INTERNATIONAL

Table 7-13: BioInvent Corporate Summary

BIOTEST AG

Table 7-14: Biotest AG Corporate Summary

BOEHRINGER INGELHEIM GMBH

Table 7-15: Boehringer Ingelheim Corporate Summary

CBT PHARMACEUTICALS

Table 7-16: CBT Corporate Summary

CELGENE

Table 7-17: Celgene Corporate Summary

CELLDEX THERAPEUTICS

Table 7-18: Celldex Therapeutics Corporate Summary

CELLTRION, INC.

Table 7-19: Celltrion Corporate Summary

COHERUS BIOSCIENCES, INC

Table 7-20: Coherus Biosciences Corporate Summary

CYTODYN

Table 7-21: CytoDyn Corporate Summary

EISAI

Table 7-22: Eisai Corporate Summary

ELEVEN BIOTHERAPEUTICS

Table 7-23: Eleven Biotherapeutics Corporate Summary

ELI LILLY & CO.

Table 7-24: Eli Lilly & Co. Corporate Summary

FIBROGEN INC.

Table 7-25: FibroGen Inc. Corporate Summary

FIVE PRIME THERAPEUTICS

Table 7-26: Five Prime Therapeutics Corporate Summary

FUJIFILM KYOWA KIRIN BIOLOGICS

Table 7-27: Fujifilm Kyowa Kirin Biologics Corporate Summary

GENMAB A/S

Table 7-28: Genmab A/S Corporate Summary

GILEAD SCIENCES

Table 7-29: Gilead Sciences Corporate Summary

GLAXOSMITHKLINE PLC

Table 7-30: GlaxoSmithKline Corporate Summary

HUMANIGEN, INC. (PREVIOUSLY KALOBIOS PHARMACEUTICALS)

Table 7-31: Humanigen Inc. Corporate Summary

IMMUNE PHARMACEUTICALS

Table 7-32: Immune Pharmaceuticals Corporate Summary

IMMUNOGEN INC.

Table 7-33: ImmunoGen Inc. Corporate Summary

IMMUNOMEDICS INC.

Table 7-34: Immunomedics Inc. Corporate Summary

INNATE PHARMA

Table 7-35: Innate Pharma Corporate Summary

INTERVEXION THERAPEUTICS

Table 7-36: InterveXion Therapeutics Corporate Summary

JOHNSON & JOHNSON

Table 7-37: Johnson & Johnson Corporate Summary

KYOWA HAKKO KIRIN CO, LTD

Table 7-38: Kyowa Hakko Kirin Corporate Summary

MACROGENICS

Table 7-39: MacroGenics Corporate Summary

MAPP BIOPHARMACEUTICAL

Table 7-40: Mapp Corporate Summary

MERCK & COMPANY

Table 7-41: Merck Corporate Summary

MERRIMACK PHARMACEUTICALS

Table 7-42: Merrimack Corporate Summary

MOMENTA PHARMACEUTICALS INC

Table 7-43: Momenta Pharmaceuticals Corporate Summary

MORPHOSYS

Table 7-44: MorphoSys Corporate Summary

MORPHOTEK

Table 7-45: Morphotek Corporate Summary

MYLAN N.V.

Table 7-46: Mylan Corporate Summary

NASCENT BIOTECH

Table 7-47: Nascent Biotech Corporate Summary

NEURIMMUNE

Table 7-48: Neurimmune Corporate Summary

NORDIC NANOVECTOR

Table 7-49: Nordic Nanovector Corporate Summary

NOVARTIS/SANDOZ

Table 7-50: Novartis/Sandoz Corporate Summary

NOVIMMUNE SA

Table 7-51: Novimmune SA Corporate Summary

ONCOMED PHARMACEUTICALS

Table 7-52: OncoMed Pharmaceuticals Corporate Summary

ONCOQUEST

Table 7-53: OncoQuest Corporate Summary

ONCTERNAL THERAPEUTICS

Table 7-54: Oncternal Therapeutics Corporate Summary

PFIZER, INC.

Table 7-55: Pfizer Corporate Summary

REGENERON PHARMACEUTICALS

Table 7-56: Regeneron Corporate Summary

ROCHE

Table 7-57: Roche Corporate Summary

SAMSUNG BIOEPIS CO LTD

Table 7-58: Samsung Bioepis Corporate Summary

SANOFI

Table 7-59: Sanofi Corporate Summary

SEATTLE GENETICS

Table 7-60: Seattle Genetics Corporate Summary

SHIRE PLC

Table 7-61: Shire PLC Corporate Summary

SORRENTO THERAPEUTICS

Table 7-62: Sorrento Therapeutics Corporate Summary

TAIMED BIOLOGICS

Table 7-63: TaiMed Biologics Corporate Summary

TAKEDA ONCOLOGY

Table 7-64: Takeda Oncology Corporate Summary

TESARO

Table 7-65: TESARO Corporate Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD

Table 7-66: Teva Corporate Summary Corporate Summary

TG THERAPEUTICS

Table 7-67: TG Therapeutics Corporate Summary

THROMBOGENICS

Table 7-68: ThromboGenics Corporate Summary

UCB S.A.

Table 7-69: UCB S.A. Corporate Summary

UNUM THERAPEUTICS

Table 7-70: Unum Therapeutics Corporate Summary

VITAERIS

Table 7-71: Vitaeris Corporate Summary

XBIOTECH

Table 7-72: XBiotech Corporate Summary

XENCOR

Table 7-73: Xencor Corporate Summary

XOMA

Table 7-74: XOMA Corporate Summary

Y-MABS THERAPEUTICS

Table 7-75: Y-mAbs Therapeutics Corporate Summary
    The Worldwide Market for Mass Spectrometry in Clinical Labs, 2024
    September 11, 2024
    Worldwide Sequencer Market, 2023-2028
    August 8, 2024
    The Worldwide Market for Liquid Biopsy, 6th Edition
    December 29, 2023
    The Market for RNA Sequencing, 3rd Edition
    September 8, 2023

Related products

  • Placeholder image

    Cell Culture – The World Market for Media, Sera, and Reagents

    $3,900.00 – $7,800.00
  • Placeholder image

    Wound Care Markets, 3rd. Edition, Vol. I – Skin Ulcers

    $2,995.00 – $5,990.00
  • Placeholder image

    Protein Therapeutics: Monoclonal Antibodies, Plasma Proteins, Vaccines, and Other Treatments, Global Market

    $995.00 – $1,990.00
  • Placeholder image

    Biomarkers – A Market Briefing

    $995.00 – $3,990.00

Contact Us

  • 671 North Glebe Road, Suite 1610 Arlington, VA 22203 United States

  • Email Us

  • 703-778-3080

  • Send us a message!

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • 4 Fascinating Facts About Cancer Diagnostics March 4, 2025
  • Food Animal Diagnostics Market: Spotlight on Disease Testing Amid Bird Flu Surge February 20, 2025
  • Custom Competitive Intelligence (CI) Research: A New Strategic Imperative For Lab Diagnostics Companies  February 19, 2025
  • The Rise of Pharmacodiagnostics in the $10 Billion Global Cancer Diagnostics Market February 1, 2025
  • IVD Trends to Watch: Personalized Medicine Adds Precision to Diagnostic Testing January 2, 2025

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement
  • Privacy Settings

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
The Market and Potential for CRISPR/Cas9 Gene EditingThe Worldwide Market for Point-of-Care (POC) Testing (Infectious Disease Testing,...
Scroll to top